Mario A. Eisenberger

Papers

Total Citations

H-Index

About

Mario A. Eisenberger is a pioneering oncologist whose research has fundamentally shaped the treatment landscape for advanced prostate cancer. His work centers on the biology and clinical management of castration-resistant prostate cancer (CRPC) and the role of novel therapeutic strategies. Eisenberger is perhaps best known for his leadership in the landmark TAX 327 trial, which established docetaxel as the first chemotherapy to improve survival in men with metastatic CRPC—a breakthrough that transformed a previously chemo-resistant disease into a treatable condition. His contributions extend to the study of androgen receptor signaling inhibitors and the integration of immunotherapy in prostate cancer. With over 30,000 citations, his work has had a profound and lasting impact on clinical practice. Notably, he has also explored the potential of stereotactic ablative radiation therapy for oligometastatic prostate cancer, pushing the boundaries of localized treatment in advanced disease. A dedicated mentor and clinician at Johns Hopkins, Eisenberger’s legacy is defined by his relentless pursuit of therapies that extend and improve the lives of patients with prostate cancer.